Cargando…
Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1
Drug resistance in breast cancer (BC) cells continues to be a stern obstacle hindering BC treatment. Adriamycin (ADR) is a frequently employed chemotherapy agent used to treat BC. The exosomal transfer of microRNAs (miRNAs) has been reported to enhance the drug-resistance of BC cells. Herein, we fir...
Autores principales: | Pan, Xiaoping, Hong, Xiaolv, Lai, Jinguo, Cheng, Lu, Cheng, Yandong, Yao, Mingmei, Wang, Rong, Hu, Na |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212418/ https://www.ncbi.nlm.nih.gov/pubmed/32426266 http://dx.doi.org/10.3389/fonc.2020.00441 |
Ejemplares similares
-
Retraction: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1
Publicado: (2021) -
METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner
por: Pan, Xiaoping, et al.
Publicado: (2021) -
MicroRNA‐221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling
por: Yin, Yingchun, et al.
Publicado: (2020) -
Down-Regulated Exosomal MicroRNA-221 – 3p Derived From Senescent Mesenchymal Stem Cells Impairs Heart Repair
por: Sun, Ling, et al.
Publicado: (2020) -
Plasma microRNA-221-3p as a biomarker for POCD after non-cardiac surgery
por: Fan, Di, et al.
Publicado: (2022)